
Robert Turner Schooley MD
HIV/AIDS Medicine, International Health, Travel & Tropical
Professor, Medicine, UCSD School of Medicine
Join to view full profile
University of California San DiegoStein Clinical Research BuildingLa Jolla, CA 92093
Phone+1 858-246-2693
Dr. Schooley is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Robert Schooley is an infectious disease specialist based in La Jolla, CA, with subspecialties in HIV/AIDS medicine, international health, bacteriophage therapy and tropical medicine. He completed his medical education and training at prestigious institutions including Johns Hopkins University, the National Institutes of Health Clinical Center, and Harvard Medical School. Dr. Schooley has held various roles, such as Staff Physician at UC San Diego Health since 2005 and previously at the Rocky Mountain Regional Veterans Affairs Medical Center. His research interests include virology and bacteriophage therapy, with publications in prominent journals like Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, Science and Nature. He has served as principal investigator in clinical trials focusing on respiratory viruses, HIV and antimicrobial resistant bacterial infections. Dr. Schooley's accolades include being named in Who's Who in America and receiving the Gold Doc award from the Arnold P. Gold Foundation. He is a 2024 recipient of UC San Diego's Reveille Medal.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1979 - 1981
National Institutes of Health Clinical CenterFellowship, Infectious Disease, 1976 - 1979
Johns Hopkins UniversityResidency, Internal Medicine, 1974 - 1976
Johns Hopkins UniversityInternship, Internal Medicine, 1974 - 1975
Johns Hopkins University School of MedicineClass of 1974
Certifications & Licensure
CO State Medical License 1990 - 2027
CA State Medical License 2005 - 2026
MD State Medical License 1974 - 1983
American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Who's Who in America 1995-2018
- Gold Doc Arnold P. Gold Foundation, 2009
- Chief Residents’ Clinical Teaching University of California, San Diego, 2007
Clinical Trials
- A Phase I/II Trial of Vaccine Therapy of HIV-1 Infected Individuals With 50-500 CD4 Cells/mm3
- A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
- Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients
Publications & Presentations
PubMed
- Oral lipid prodrug V2043 (1--octadecyl-2--benzyl--glyceryl-P-remdesivir nucleoside) protects mice from lethal dengue infection.Alex E Clark, Jonathan R Erlich, James R Beadle, Rachel E McMillan, Jialei Xie
Antimicrobial Agents and Chemotherapy. 2026-09-02 - First-in-Human Adjunctive Bacteriophage Therapy for Malakoplakia.Saima Aslam, Aleah Brubaker, Mita Shah, Thomas C S Martin, Tyler Mandt
Clinical Infectious Diseases. 2026-08-11 - Survival differences and artemisinin resistance in severe malaria among HIV coinfected patients: data from Mozambique.Irina Mendes de Sousa, Erin McArthur, Lúcia Chambal, Kevan Akrami, Annie N Cowell
Medrxiv. 2026-06-22
Journal Articles
- Successful Treatment of Antibiotic Resistant Poly-Microbial Bone Infection with Bacteriophages and Antibiotics CombinationRobert Schooley, MD, Clinical Infectious Diseases
- Oa the Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and MozambiqueRobert Schooley, MD, The American Journal of Tropical Medicine and Hygiene
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Post-Treatment Controllers Identified from 14 Clinical StudiesElizabeth Connick, Jonathan Z Li, Paul Volberding, Daniel R Kuritzkes, Robert T Schooley, David Margolis, Daniel Skiest, John W Mellors, Ronald Mitsuyasu, Ann C Collie..., The Journal of Infectious Diseases
Books/Book Chapters
Press Mentions
Stacking CDC’s Vaccine Committee with Losers Threatens 'A Disaster'June 17th, 2025
Q&A on New COVID-19 Vaccine PoliciesJune 5th, 2025
2-in-1 COVID-Flu Vaccine Looks Promising in Trial — but Experts Say Approval May Be DelayedMay 19th, 2025
Grant Support
- Orally Bioavailable Antiviral Drugs with Broad Pandemic Virus ActivityUNIVERSITY OF CALIFORNIA, SAN DIEGO2021–2031
- Orally Bioavailable Antiviral Drugs with Broad Pandemic Virus ActivityUNIVERSITY OF CALIFORNIA, SAN DIEGO2021–2031
- Orally Bioavailable Antiviral Drugs with Broad Pandemic Virus ActivityUNIVERSITY OF CALIFORNIA, SAN DIEGO2021–2031
- Orally Active Nucleoside Phosphonates For Hepatitis C VirusNational Institute Of Allergy And Infectious Diseases2009–2012
- Multiplex Nucleic Acid Detection Devices For The Diagnosis Of Respiratory VirusesNational Institute Of Allergy And Infectious Diseases2007–2011
Committees
- Chair, Microbiology and Infectious Diseases, B 2019 - 2023
- Chair, NIH Drug Discovery and Resistance (DDR) Study Section 2011 - 2013
- Member, Scientific Advisory Board, PEPFAR, US Department of State 2011 - 2013
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: